Endocrine Abstracts

Background: We observed patients with well-differentiated NETs who received PRRT with 177Lu-dotatate and later developed rapid disease progression with biopsy-proven histologic transformation to NECs, an outcome that has not been previously described. In this series, we characterize the clinicopathologic features and outcomes of patients whose tumors underwent poorly-differentiated transformation.Methods: After obtaining IRB approval, we condu...

Background: 177Lu-DOTATATE is an FDA and Health Canada-approved treatment option for metastatic, progressive GEPNET patients. 177Lu-DOTATATE is now often considered the treatment of choice for small bowel/midgut patients who have progressed on somatostatin analogs (SSA). Despite 177Lu- DOTATATE’s impressive disease stabilization, many patients will eventually progress. Progression after prior use of PRRT does not necessarily render these tumors resistant to future PRRT tr...

Background: Although anti-VEGF RTKIs have been tested in patients with NETs over the last 2 decades, no study to date has benchmarked efficacy and toxicity of these drugs in this patient population.Methods: A literature search was performed to identify all phase II and phase III studies of anti-VEGF RTKIs in patients with NETs published between January 1, 2000 – July 31, 2021. Major trial databases (e.g. Medline, EMBASE, Cumulative Index of Nursing ...

Background: 10% of pancreatic neuroendocrine tumors (pNETs) are thought to be related to inherited syndromes, (MEN1, MEN4, VHL, NF1 and TSC). Growing evidence suggests, that clinically sporadic appearing pNETs can harbor germline mutations. Here, we report the prevalence of pathological/likely pathological germline variants (P/LP) in 2 cohorts: 1) High-risk and 2) Unselected.Methods: We retrospectively collected clinical data of pNET patients seen at MD ...